Hydrochloric Acid → HCID 72549752, compound
Reaction equation
[CH3:1][C:2]1[CH:7]=[C:6]([C:8]2[CH:13]=[CH:12][C:11]([C:14]([F:17])([F:16])[F:15])=[CH:10][CH:9]=2)[N:5]=[C:4]([C@H:18]2[CH2:22][CH2:21][C@:20]3([CH2:26][CH2:25][NH:24][C:23]3=[O:27])[N:19]2C(OC(C)(C)C)=O)[N:3]=1.CC1C=C(C2C=CC(C(F)(F)F)=CC=2)N=C([C@H]2CC[C@]3(CCNC3=O)N2)N=1.C(Cl)(Cl)[Cl:63].Cl>CCOCC>[ClH:63].[CH3:1][C:2]1[CH:7]=[C:6]([C:8]2[CH:9]=[CH:10][C:11]([C:14]([F:15])([F:16])[F:17])=[CH:12][CH:13]=2)[N:5]=[C:4]([C@H:18]2[CH2:22][CH2:21][C@:20]3([CH2:26][CH2:25][NH:24][C:23]3=[O:27])[NH:19]2)[N:3]=1Participants
6
Reactant 4
Product 1
Reagents, catalysts & solvents 1
Procedure
In a similar manner, tert-butyl (2R,5R)-2-[4-methyl-6-[4-(trifluoromethyl)phenyl]pyrimidin-2-yl]-6-oxo-1,7-diazaspiro[4.4]nonane-1-carboxylate (37 mg) was converted first to the free base (2R,5R)-2-[4-methyl-6-[4-(trifluoromethyl)phenyl]pyrimidin-2-yl]-1,7-diazaspiro[4.4]-nonan-6-one (27 mg); m/z 377 (M+H+); Optical Rotation α[D/20)]=+32.1 (c=0.56, CHCl3). This material was subsequently treated with HCl in ether to form (2R,5R)-2-[4-methyl-6-[4-(trifluoromethyl)-phenyl]pyrimidin-2-yl]-1,7-diazaspiro[4.4]nonan-6-one hydrochloride (E42) (32 mg); m/z 377 (M+H+).
Sources & evidence
- ORD record
- ord-a1b967c2e1f840639ba3ab3050becc96
- Source dataset
- uspto-grants-2016_04
- Patent number
- US09309254B2
Reaction notes
Loading…